NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years

Not Yet RecruitingPhase 4

Sponsor: Tor Biering-Sørensen

Conditions: COVID-19, Influenza

Interventions: mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)

Countries: Denmark, Spain

The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza vaccine/Efluelda® and mRNA-1273/Spikevax®) among adults aged 65 years and older.

Eligibility overview

Sex: ALL

Age: 65 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Age ≥65 years at the time of vaccination
2. Self-reported ability to understand written and spoken English or Danish (Denmark only) or Spanish or Galician (Spain only)
3. Informed consent form has been signed and dated

Exclusion Criteria:

* There are no specific exclusion criteria for this study

Locations (3)

Hellerup, Denmark
Søborg, Denmark
Santiago de Compostela, A Coruña, Spain